This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Otsuka Pharmaceuticals Pays Up for Astex

NEW YORK ( TheStreet) - Japan's Otsuka Pharmaceutical Co. Ltd. announced an $886 million deal for oncology drug specialist Astex Pharmaceuticals Inc. to bolster its pipeline before the loss of a key patent.

Otsuka,of Tokyo, said it would pay $8.50 per Astex share, a 27% premium to the shares' Tuesday close before rumors of a pending deal leaked. The stock gained 24% Wednesday.

"I hope that this acquisition of Astex will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field, through the acquisition of Astex's fragment-based drug design technology at its Cambridge, England, research headquarters and its California clinical oncology R&D department," said Otsuka president Taro Iwamoto in a statement.

Astex, of Dublin, Calif., slipped to a second-quarter loss of $4.2 million, versus profit of $1.2 million in the same period a year earlier as it spent on research and failed to get royalties from a venture with MGI Pharma Inc. Revenue slid 17% to $16.6 million in the period.

The agreement will help Otsuka defend against the loss of its patent on Abilify, a $4.5 billion-a-year antipsychotic drug, at the end of 2014. Otsuka's last major deal came two years ago when it launched a joint venture with Copenhagen-based H. Lundbeck A/S to develop and sell five psychiatric and neuroscience products.

Lundbeck paid $200 million up front and may dole out as much as another $1.8 billion in royalties from drugs developed in the venture. They expanded the venture to include a new Alzheimer's treatment earlier this year. While two-thirds of Otsuka's sales are generated by its pharmaceuticals business, the company also has nutritional products, such as sports drinks and energy bars.

The deal is just the latest in a long string of international acquisitions by pharmaceutical companies hoping to offset expiring patents -- and Japanese companies have played a key role, bolstered by a strong yen.

Takeda Pharmaceutical Co. Ltd. in 2011 spent $12 billion on Switzerland's Nycomed International Management GmbH from a consortium of financial investors. It also spent $800 million on Philadelphia gout treatment maker URL Pharma Inc., which was also owned by financial investors.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs